Vaxart (OTCMKTS:VXRT) Stock Price Passes Below 200-Day Moving Average – What’s Next?

Vaxart, Inc. (OTCMKTS:VXRT)’s share price crossed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $0.59 and traded as low as $0.55. Vaxart shares last traded at $0.5686, with a volume of 275,711 shares traded.

Vaxart Trading Down 3.6%

The stock has a market cap of $138.04 million, a price-to-earnings ratio of 3.79 and a beta of 1.10. The stock has a 50-day moving average price of $0.67 and a two-hundred day moving average price of $0.59.

Vaxart (OTCMKTS:VXRT) last posted its quarterly earnings data on Thursday, May 7th. The biotechnology company reported $0.02 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.02. The firm had revenue of $39.23 million during the quarter, compared to analysts’ expectations of $50.50 million. Vaxart had a return on equity of 61.43% and a net margin of 14.51%.

Institutional Trading of Vaxart

A number of institutional investors and hedge funds have recently added to or reduced their stakes in VXRT. Invesco Ltd. lifted its position in Vaxart by 93.1% during the 1st quarter. Invesco Ltd. now owns 146,366 shares of the biotechnology company’s stock worth $60,000 after acquiring an additional 70,568 shares during the period. Jones Financial Companies Lllp lifted its position in Vaxart by 276,364.7% during the 1st quarter. Jones Financial Companies Lllp now owns 478,284 shares of the biotechnology company’s stock worth $196,000 after acquiring an additional 478,111 shares during the period. Goldman Sachs Group Inc. acquired a new stake in Vaxart during the 1st quarter worth about $31,000. Creative Planning acquired a new stake in Vaxart during the 2nd quarter worth about $33,000. Finally, Marshall Wace LLP acquired a new stake in Vaxart during the 2nd quarter worth about $794,000. Institutional investors and hedge funds own 18.05% of the company’s stock.

Vaxart Company Profile

Vaxart, Inc is a clinical-stage biotechnology company pioneering the development of oral recombinant vaccines administered in tablet form. Leveraging a proprietary, room-temperature-stable platform, the company aims to simplify vaccine delivery while eliciting both systemic and mucosal immune responses. Its technology is based on the replication-defective adenovirus vector system, which encodes target antigens designed to protect against a range of infectious diseases without the need for injections or cold-chain logistics.

The company’s pipeline includes multiple vaccine candidates in various stages of development.